anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Preeclampsia (PE) is a gestational complication with developed hypertension and proteinuria. Evidence showed the role of mTOR in various cellular processes. Therefore, this study aimed to evaluate the effects of MTOR polymorphisms on susceptibility, severity, and onset of Preeclampsia (PE).
METHODS AND RESULTS: A total of 250 PE pregnant women and 258 age-matched control subjects were recruited in this study. To genotype MTOR polymorphisms, the PCR-RFLP method was used. The SpliceAid 2 and PROMO tools were used for in silico analysis. The maternal MTOR rs17036508T/C polymorphism was associated with PE risk in various genetic models. There was no relationship between rs2536T/C and rs2295080T/G polymorphisms and PE. The TTC and TGC haplotypes of rs2536/ rs2295080/ rs17036508 polymorphisms were significantly higher in PE women. Subgroup analysis revealed the association between the MTOR rs2295080 variant and an increased risk of Early-onset PE (EOPE). However, the MTOR rs17036508 was associated with a higher risk of EOPE and Late- Onset PE. In addition, the MTOR rs2295080 could increase the risk of severe PE. The results of the in silico analysis showed that rs17036508 disrupted several binding motifs in the mutant sequence. The PROMO database revealed that the T to C substitution leads to the loss of the TFII-I binding site in the mutant allele.
CONCLUSION: The MTOR rs17036508T/C polymorphism was associated with PE risk. There was an association between the MTOR rs2295080 variant and an increased risk of EOPE. The MTOR rs17036508T/C and rs2295080T/C variants could disrupt several binding motifs and TFII-I binding respectively.
Venous blood samples will be taken from the patients included in the study and incubated with thiopental (dose: 100, 250, 500 and 1000µM) after appropriate procedures in the laboratory environment. . After incubation, all resuspensions will be subjected to flow cytometric analysis to evaluate erythrocyte NO synthase activity and erythrocyte-mediated NO release.
The study will involve acquiring ECG data in a cohort of up to 1,000 newborns and infants (500 controls (non-LQTS) and 500 LQTS newborns and infants) that are being seen in the Gonda SL ECG Lab (or Baldwin Building)and enrolled during their appointment for a clinically indicated 12-lead ECG. A second arm of Phase II of this study will include approaching 50 healthy subjects at the Baldwin Building to seek interest in participation which will consist of (1) 30 second device recording to help further calibrate and test the device for optimal enhancement. These 50 subjects will not be required to have a clinical or research 12-lead ECG as the investigators will be simply testing the efficiency and accuracy of the device. LQTS will be studied in order to assess the ability of the LQTS screener to accurately detect a patient with established QT prolongation in the context of distinct and varied T wave morphologies The advanced prototype will be placed in the same manner as the device used in Phase I of the study by being lightly placed on the child as pictured below. Similarly, the investigators will use ultrasound gel to obtain a better reading, if applicable. Once completed, a photograph of the torso of the child will be taken from the same views as before (one aerial view and one side view) with neither the head nor the face in the picture. Coded ECG-tracings will be transmitted to the app and shared with Blue Ox Health Corporation and Minnesota Health Solutions as done previously in phase I. Additionally, coded tracings and data from the 12-lead ECG will be shared with Blue Ox Health Corporation and Minnesota Health Solutions to aid in comparison to device tracings and optimization of the algorithm. The 12-lead ECG will be obtained from the subject's medical record and coded before being shared with collaborators. Study coordinators will also review the patient's medical record to determine whether the participants have been diagnosed with a genetic disease.
Subjects in F arm (Group 2 Non-menthol) will remain abstinent from cigarette smoking for the duration of the study during both the confinement and ambulatory phases. There will be 30 subjects assigned to this arm with a randomization ratio of 1.
PCT No. PCT/NL96/00245 Sec. 371 Date May 11, 1998 Sec. 102(e) Date May 11, 1998 PCT Filed Jun. 14, 1996 PCT Pub. No. WO97/00064 PCT Pub. Date Jan. 3, 1997The invention relates to a method for manufacturing a dental restoration, comprising the steps of applying a powdered dental metal comprising composition to a refractory model mass, which powdered dental metal consist of at least three alloys each having a different solidus temperature, the difference between the successive solidus temperatures always ranging between 25 and 100 DEG  C., heating the powdered dental material in such a manner that one porous mass is formed, and infiltrating the porous mass with a filler metal alloy in such a manner that the refractory model mass is provided with a homogenous metal coating.
INTRODUCTION: Spheno-orbital meningiomas (SOMs) represent a distinct subtype of meningioma characterized by their unique multi-compartmental invasion pattern. Previous studies have investigated correlations between SOMs and visual manifestations. However, our comprehension of pain associated with SOMs remains limited. This study aims to provide insight into the pathophysiology underlying SOM-related pain through measurements of tumor volume and superior orbital fissure (SOF) narrowing.
METHODS: This retrospective study included patients who underwent surgical resection of a SOM between 2000 and 2022. Preoperative CT and/or MRI scans were analyzed, and the tumor volume of each segment was measured. Bony 3D reconstructions were used to measure the area of the SOF, and SOF narrowing was calculated.
RESULTS: The study cohort included 66 patients diagnosed with SOMs, among which 25.8% (n = 17) presented with pain. Postoperatively, 14/17 (82.4%) of patients reported pain improvement. There was no significant correlation between the total volume or the volume of tumor within each compartment and the presence of pain on presentation (p > 0.05). The median SOF narrowing was significantly different between patients presenting with and without tumor-associated pain with median of 11 mm2 (IQR 2.8-22.3) and 2 mm2 (IQR 0-6), respectively (p = 0.005). Using logistic regression, a significant correlation between the degree of SOF narrowing and the presence of SOM-associated pain on presentation was identified, with an aOR of 1.2 (95% CI 1.12-1.3, p = 0.02).
CONCLUSION: While the exact cause of tumor-associated pain remains unclear, SOF narrowing seems to play a role in pain among SOM patients. Based on the radiological characteristics, SOF neurovascular decompression is recommended in SOM patients.
The present invention relates to a technique and a device for extracting the effective components of Tibet oriental wormwood and a method for preparing a Tibet oriental wormwood tablet. The technique comprises the procedures of continuous extraction, concentration by a concentration pot, concentration by an open pan, drying, pulverization, etc. Tibet oriental wormwood is used as raw materials, and ethanol is used as an extraction agent. A continuous extraction device used in the continuous extraction procedure is characterized in that the continuous extraction device is provided with two extraction pots, the extraction pots are connected together by an extract flow pipe, and a heating chamber is arranged on the bottoms of the extraction pots. The method for preparing a Tibet oriental wormwood tablet is characterized in that the product can be prepared from 45 to 90% of extract powder and 10 to 55% of auxiliary material by the procedures of mixing, uniform stirring, moistening, drying, tabletting, molding, etc. The present invention has the advantages of little ethanol consumption, low energy consumption and capability of continuous extraction.
Patients 65 years and over, particularly those with hypertension, may be at increased risk for developing hypotension while undergoing anesthesia with SENSORCAINE/ SENSORCAINE WITH EPINEPHRINE. 

In clinical studies of bupivacaine, elderly patients reached the maximal spread of analgesia and maximal motor blockade more rapidly than younger adult patients. 

Differences in various pharmacokinetic parameters have been observed between elderly and younger adult patients [see Clinical Pharmacology (12.3)]. 

This product is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Elderly patients may require lower doses of SENSORCAINE/ SENSORCAINE WITH EPINEPHRINE.
The antidiuretic property of diazoxide may lead to significant fluid retention. In patients with compromised cardiac reserve, fluid retention may precipitate congestive heart failure. If fluid retention develops, manage according to standards of care. 

Co-administration of PROGLYCEM with thiazides may potentiate the hyperglycemic and hyperuricemic actions of diazoxide (see DRUG INTERACTIONS and ANIMAL PHARMACOLOGY AND/OR TOXICOLOGY).

Ketoacidosis and nonketotic hyperosmolar coma have been reported in patients treated with PROGLYCEM, usually during intercurrent illness. Prompt recognition and treatment are essential (see OVERDOSAGE), and prolonged surveillance following the acute episode is necessary because of the long drug half-life of approximately 30 hours. Advise patients to monitor urine glucose and ketones and to promptly report abnormal findings and symptoms of ketoacidosis to their healthcare provider. Transient cataracts occurred in association with hyperosmolar coma in an infant, and subsided on correction of the hyper-osmolarity. Cataracts have been observed in several animals receiving daily dosages of intravenous or oral diazoxide.

The development of abnormal facial features in four children treated chronically (>4 years) with PROGLYCEM for hypoglycemia hyperinsulinism in the same clinic has been reported.

Pulmonary Hypertension in Neonates and Infants

There have been postmarketing reports of pulmonary hypertension occurring in infants and neonates treated with diazoxide. The cases were reversible upon discontinuation of diazoxide. Monitor patients, especially those with risk factors for pulmonary hypertension, for respiratory distress and discontinue PROGLYCEM if pulmonary hypertension is suspected.
The invention relates to a hepatitis c virus (HCV) cell entrance inhibitory peptide ZTE2 sequence and application. Polypeptides are 15 peptides synthesized according to an amino acid sequence of an envelope protein E2 of an HCV genetype 2a reference strain JFH-1, and the purity is larger than 85%. According to the hepatitis c virus (HCV) cell entrance inhibitory peptide ZTE2 sequence, amino acid sequences, shown in Seq ID:No.1 and Seq ID:No.2, of the polypeptides E2-78 and E2-79 are found, ten overlapped amino acids are named as ZTE2, and the sequence is Seq ID:No.3. When the dosage is 10 nM, the inhibition ratio to HCVcc(Jc1p7NS2Gluc2a) infections can reach more than 80%, and it is determined that the effective dose (ED50) of half of the four peptides is about 5 nM through analysis. Under the polypeptide and HCVcc co-incubation (0 h) or HCVcc post-infection (+4 h) co-incubation condition, the polypeptides can obviously restrain the HCV infections, and core sequences of the inhibitory peptides are preliminarily determined through synthesis, inhibiting, screening and analysis of truncated peptides. The hepatitis c virus (HCV) cell entrance inhibitory peptide ZTE2 sequence is of important significance, can help a person to know the process and a mechanism of the new virus infections, and can provide a new design thought for blocking the HCV infection.
BACKGROUND AND PURPOSE: Remote ischaemic preconditioning (rIPC) for cardioprotection is severely impaired in diabetes, and therapeutic options to restore it are lacking. The vascular endothelium plays a key role in rIPC. Given that the activity of endothelial nitric oxide synthase (eNOS) is inhibited by proline-rich tyrosine kinase 2 (Pyk2), we hypothesized that pharmacological Pyk2 inhibition could restore eNOS activity and thus restore remote cardioprotection in diabetes.
EXPERIMENTAL APPROACH: New Zealand obese (NZO) mice that demonstrated key features of diabetes were studied. The consequence of Pyk2 inhibition on endothelial function, rIPC and infarct size after myocardial infarction were evaluated. The impact of plasma from mice and humans with or without diabetes was assessed in isolated buffer perfused murine hearts and aortic rings.
KEY RESULTS: Plasma from nondiabetic mice and humans, both subjected to rIPC, caused remote tissue protection. Similar to diabetic humans, NZO mice demonstrated endothelial dysfunction. NZO mice had reduced circulating nitrite levels, elevated arterial blood pressure and a larger infarct size after ischaemia and reperfusion than BL6 mice. Pyk2 increased the phosphorylation of eNOS at its inhibitory site (Tyr656), limiting its activity in diabetes. The cardioprotective effects of rIPC were abolished in diabetic NZO mice. Pharmacological Pyk2 inhibition restored endothelial function and rescued cardioprotective effects of rIPC.
CONCLUSION AND IMPLICATIONS: Endothelial function and remote tissue protection are impaired in diabetes. Pyk2 is a novel target for treating endothelial dysfunction and restoring cardioprotection through rIPC in diabetes.
<P>PROBLEM TO BE SOLVED: To provide a supplement set for reducing at least one of symptoms out of dysmenorrhea and premenstrual syndrome.  <P>SOLUTION: The supplement set is used for reducing at least one of symptoms out of dysmenorrhea and premenstrual and contains at least a supplement for an ovarian follicle term ingested in the ovarian follicle term. Preferably, the supplement set further contains a supplement for a menstrual term ingested in the menstrual term and a supplement for a luteal phase ingested in the luteal phase. Especially, the supplement for the ovarian follicle term contains vitamin A, β-carotene, cystine, vitamin B6, vitamin B12, vitamin C, vitamin E, folic acid and the like. The supplement for the menstrual term further contains hesperidin, raspberry fruit juice, a hawthorn (crataegus oxyacantha) extract, a grape seed extract, CA, Mg and Fe. The supplement for the luteal phase further contains theanine, soybean isoflavone and the like.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
The primary aim of this project was to create and evaluate a theoretically-based, interactive multimedia program for women aged 35-55 to assist them in avoiding unintended pregnancy and sexually transmitted infections (STIs). The intervention, titled "Women's Reproductive Health: A guide to staying healthy," addressed these concerns across the life span and was designed to increase knowledge about (a) pregnancy risk; (b) STI risk; (c) strategies to prevent STIs and unintended pregnancy; (d) influences of sexual partners on risk reduction decisions and behaviors; (e) partner communication techniques; and (f) health care provider communication techniques.Overall features of the program include video, interactive tools, animations, text information pages, and various links both across and within specific modules to link related information. A feature titled "My Notes" allowed the user to save content from the program into an easily retrievable repository.

Motivational videos featuring friendly mid-life hosts could be viewed on the first page of each module, as well as on the home page and topic introduction pages. These videos not only provided specific information about the content, they also provided message framing and set the tone of the program segment. Other videos included testimonials on topics such as contraceptive methods, sexually transmitted infections, and other health information. Interactive materials include an assessment checklist for STI risk, a quiz to help the user identify the types of birth control methods that best fit her lifestyle and preferences, as well as several checklists
An insulin infusion device and a related operating method are disclosed. The method obtains a blood glucose (BG) measurement of a blood sample from a user, displays the BG measurement on a display element of the infusion device, and receives a confirmation input that indicates user acceptance of the displayed BG measurement. In response to the confirmation input, a glucose sensor calibration routine is automatically initiated, and an insulin bolus calculation is automatically initiated. The calibration routine and the bolus calculation use the confirmed BG measurement. The method continues by controlling delivery of insulin, in accordance with the calculated insulin bolus, from a fluid reservoir of the insulin infusion device. The sensor calibration routine and the insulin bolus calculation are both performed without any additional user involvement or interaction with the user interface other than the user acceptance of the displayed BG measurement.
PURPOSE:To titled remedy, containing Houttuynia Herba, Licorice and galla rhois and/or galla halepensis as active ingradient and capable of exhibiting antieczematous action excellent in both of dry and weeping eczemas. CONSTITUTION:A remedy for eczema containing Houttuynia Herba, Licorice and galla rhois and/or galla halepensis as active ingredients. Chinese medicinal pharmaceuticals, e.g. CHUOKO (ointment containing sesame oil, beeswax, Cork tree bark, etc.), SHIUNKO (ointment containing sesame oil, Japanese angelica root, Lithospermi Radix, lard, etc.), etc., have little side effect and effect thereof is mild. Since the effect is surely produced, the pharmaceuticals are extensively used. However, there are disadvantages of not always being suitable for weeping eczema. this remedy for eczema is applicable even to weeping eczema, hardly causing any side effect as found in steroidal pharmaceuticals. The ratio of the crude drugs blended in this pharmaceutical based on 100pts.wt. Houttuynia Herba is 5-2,000pts.wt. Licorice and 10-3,000pts.wt. total of the galla rhois and/or galla halepensis.
A. The Doyle splint will be places in both nostrils of the patient after septoplasty. The doyle splints will be removed 6 days after surgery as per standard of care. No other procedures will be changed during the surgery.
Amphotericin B 0.7 mg/kg for 14 day followed by fluconazole 400 mg daily for 8 weeks. For subjects in the standard therapy arm whose Amphotericin B dose is continued beyond 14 days, fluconazole initiation will be delayed.
BACKGROUND: We aimed to identify hub genes in chronic obstructive pulmonary disease (COPD) plasma through the exploration of a putative miRNA-mRNA regulatory network.
METHODS: Three datasets (GSE24709, GSE102915, GSE136390) were utilized to discern differentially expressed miRNAs (DEMs) between COPD and normal plasma. miRNET was employed to predict the potential targets of DEMs. Subsequent GO and KEGG analyses were conducted using DAVID. For the construction of the protein-protein interaction (PPI) network and screening of hub genes, STRING and Cytoscape were employed. The expression validation was assessed through GSE56768.
RESULTS: The results revealed 395 genes targeted by up-regulated DEMs and 234 genes targeted by down-regulated DEMs. The target genes exhibited significant enrichment in the PI3K-Akt signaling pathway and the p53 signaling pathway. Through the validation of hub genes' expression, we proposed two potential miRNA-mRNA interactions: miR-126-5p/miR-495-3p/miR-193b-3p - YWHAZ and miR-937-5p/miR-183-5p/miR-34c-5p/miR-98-5p/miR-525-3p/miR-215-5p - ACTB.
CONCLUSIONS: In conclusion, our study posits potential miRNA-mRNA interactions in COPD by analyzing datasets from public databases, contributing valuable insights into the understanding of COPD pathogenesis and potential therapeutic avenues.
BACKGROUND Retinopathy of prematurity (ROP), originally described as retrolental fibroplasia, represents an abnormal growth of blood vessels in the premature retina that can occur in response to oxygen therapy. The association between ROP and invasive mechanical ventilation has been widely studied in the literature; however, the relationships between different types of ventilation and ROP have not been as well documented. This study aimed to compare the association of ROP incidence with mechanical ventilation (MV), nasal continuous positive airway pressure (nCPAP), and high-flow nasal cannula (HFNC) therapies in 130 pre-term infants with gestational ages <32 weeks. MATERIAL AND METHODS The study includes 130 premature newborns, out of which 54 underwent MV therapy, either alone or in combination with nCPAP or HFNC therapy, 63 underwent nCPAP therapy, either alone or in combination with MV or HFNC therapy, and 23 underwent HFNC therapy, either alone or in combination with MV or nCPAP therapy. The relationships between ROP and the 3 types of ventilation were analyzed by univariate followed by multivariate logistic regression. RESULTS When adjusting for covariates, only nCPAP and birth weight were significantly associated with ROP, the former being a strong risk factor, with an adjusted odds ratio (AOR) of 7.264 (95% CI, 2.622-20.120; P<0.001), and the latter being a weak protective factor, with an AOR of 0.998 (95% CI, 0.996-0.999; P<0.05). CONCLUSIONS The results showed nCPAP was a strong ROP risk factor, birth weight was a weak ROP protective factor, and MV and HFNC were not significantly associated with increased ROP risk.
The invention discloses a fish oil enteric coated microcapsule and a preparing method thereof. The enteric coated microcapsule is mainly prepared from raw materials of 200-400 parts of fish oil 200-400 parts of lecithin, 100-200 parts of glycerinum, 2-5 parts of natural vitamin E, 1-2 parts of lemon oil, 100-200 parts of sodium alginate and 1000-1300 parts of calcium amino acid chelate. The sodium alginate and the lecithin have an emulsifying effect, the glycerinum has an emulsification assisting effect, and the fish oil is emulsified by the sodium alginate, the lecithin and the glycerinum. When the sodium alginate substitutes with calcium ion in calcium water solution, calcium alginate which does not dissolve in water is formed to wrap the fish oil to form the enteric coated microcapsule, and then the enteric coated microcapsule is filled into a hard capsule. Thus, no fishy smell goes out the stomach reversely. Furthermore, the fish oil enteric coated microcapsule is easy to absorb, high in stability and long in valid period.
Blockage of the transverse abdomen (TAP) promotes excellent analgesia of the abdominal wall and the parietal peritoneum. The meta-analyzes in adults demonstrate improved of postoperative pain and analgesic´s consumption. There are few studies on TAP block in open appendectomies and laparoscopic in pediatrics, they show good results. There is a consensus of the best anesthetic volume for good infiltration of the TAP block, but there are still doubts in the literature about the best concentration of local anesthetics of long duration. The main objective of this prospective, randomly distributed and double-blind clinical trial is to evaluate two concentrations of 0.25% and 0.5% ropivacaine with a volume of 0.4 ml / kg in pain control and the analgesic consumption through 24 hours observation in open Appendectomy in children between 6 and 16 years. 3 groups were being compared: the control group has received no blockade, the other two groups have received TAP blocks if ropivacaine 0,25% and 0,5% 0.4ml/kg. All pacients patients received the same protocols (anesthesia and analgesia). The provided analgesia was dipyrone every 6 hours and ketoprofen every 8 hours, and rescue analgesia was tramadol every 4hours if it were required. The FACE pain scale was used to evaluate the postoperative pain.